OUTSET MEDICAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.4 USD | +0.84% |
|
+3.45% | -55.64% |
| 17/04 | Outset Medical and U.S. Renal Care Announce Multi-Year Agreement to Accelerate and Grow Home Dialysis Across the U.S | CI |
| 08/04 | BTIG Initiates Outset Medical at Buy Rating With $6 Price Target | MT |
| Sales 2024 * | 148M 12.37B | Sales 2025 * | 174M 14.53B | Capitalization | 124M 10.35B |
|---|---|---|---|---|---|
| Net income 2024 * | -130M -10.85B | Net income 2025 * | -122M -10.18B | EV / Sales 2024 * | 0.27 x |
| Net cash position 2024 * | 84.74M 7.07B | Net cash position 2025 * | 80.73M 6.74B | EV / Sales 2025 * | 0.25 x |
| P/E ratio 2024 * |
-1.02
x | P/E ratio 2025 * |
-1.1
x | Employees | 480 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.18% |
More Fundamentals
* Assessed data
More news
Latest transcript on Outset Medical, Inc.
More recommendations
More press releases
| 1 day | +0.84% | ||
| 1 week | +3.45% | ||
| Current month | +8.11% | ||
| 1 month | +8.11% | ||
| 3 months | -31.43% | ||
| 6 months | -24.76% | ||
| Current year | -55.64% |
1 week
2.28
2.61
1 month
1.922.71
Current year
1.925.88
1 year
1.9224.13
3 years
1.9260.33
5 years
1.9266.96
10 years
1.9266.96
| Managers | Title | Age | Since |
|---|---|---|---|
Leslie Trigg
CEO | Chief Executive Officer | 53 | 01/13/01 |
Nabeel Ahmed
DFI | Director of Finance/CFO | 48 | 01/20/01 |
| Chief Tech/Sci/R&D Officer | - | 23/21/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leslie Trigg
CEO | Chief Executive Officer | 53 | 01/13/01 |
Patrick Hackett
BRD | Director/Board Member | 63 | 01/19/01 |
D. Grossman
BRD | Director/Board Member | 63 | 01/14/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 2.4 | +0.84% | 402,980 |
| 25/24/25 | 2.38 | -6.67% | 806,581 |
| 24/24/24 | 2.55 | +3.66% | 769,961 |
| 23/24/23 | 2.46 | +5.13% | 645,842 |
| 22/24/22 | 2.34 | +0.86% | 527,806 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Outset Medical, Inc. is a medical technology company. The Company offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. The Company designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by virtually anyone. The Tablo system comprises components, which include Tablo Console, Tablo Cartridge and Tablo Data Ecosystem. Tablo Console is a compact, mobile and versatile machine consisting of an integrated water purification, on-demand dialysate production system and touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.
Calendar
09/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.4
USD
Average target price
5.786
USD
Spread / Average Target
+141.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -55.64% | 124M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +2.43% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- OM Stock
